HIGH-DOSE IMMUNOSUPPRESSION WITH THIOTEPA AND CYCLOPHOSPHAMIDE FOLLOWE
HIGH-DOSE IMMUNOSUPPRESSION WITH THIOTEPA AND CYCLOPHOSPHAMIDE FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Thiotepa
DNA inhibitor
- Cyclophosphamide anhydrous
- Filgrastim
Granulocyte colony stimulating factor receptor agonist
What it measured
Main measures
· safety and feasibility of high-dose immunosuppression provided by the conditioning regimen with Thiotepa and Cyclophosphamide followed by Autologous Stem Cell Transplantation (CTCAE, TRM evaluations);
SafetyFeasibility
Who could take part
MS (type not specified)
Show the full criteria
Inclusion criteria
Inclusion: · multiple sclerosis defined by Mc Donald criteria; Exclusion: · previous treatment with TBI or TLI;
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
· safety and feasibility of high-dose immunosuppression provided by the conditioning regimen with Thiotepa and Cyclophosphamide followed by Autologous Stem Cell Transplantation (CTCAE, TRM evaluations);
Loading reviews and guidelines…
Related trials
- Therapeutic Monitoring of Drugs Used in the Treatment of Multiple Scle
Phase 4 · Status unknown
No results found
- A phase IV, unicentric, open label clinical trial to evaluate the defa
Phase 4 · Withdrawn
Stopped
- AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes
Phase 1 · Recruiting
Still running
- Relationship Between Oral DMT Burden and Adherence in MS
Status unknown
No results found
- Physical and Cognitive Performance During the Two First Years of Lemtr
Completed
Paper found, not read
- Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers
Status unknown
Paper found, not read
History
Started
Jan 2008